Project Grant R01GM164615
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $528,000 Project Grant award dated April 15, 2026, from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The award funds fundamental research investigating histone glycation as a dynamic epigenetic mark, with work extending through January 31, 2031. The research focuses on understanding how non-enzymatic covalent...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received $880,000 in federal funding through a Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, with a completion date of May 31, 2030. The award supports fundamental research investigating the mechanisms of lipid droplet (LD) protein targeting in human cells. The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded $292,028 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) beginning August 1, 2025, and concluding July 31, 2030. This five-year Project Grant supports research investigating genome instability associated with focal oncogene amplification (OA) and the development of therapeutic strategies to address treatment-resistant cancers. The research deliverables include...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $609,493 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded June 1, 2025, with a completion date of May 31, 2030. This five-year research initiative will generate fundamental scientific knowledge regarding the protein machinery and molecular mechanisms underlying lipid droplet (LD)...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $323,860 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on August 18, 2025, with completion targeted for April 30, 2028. The grant supports research investigating the role of mutagenic DNA repair mechanisms, specifically microhomology-mediated end joining (MMEJ), during cancer cell persistence and acquired drug resistance. The research addresses a critical gap in...
- Federal Project Grant Award Summary The Salk Institute for Biological Studies received a $795,143 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective May 4, 2026 through April 30, 2031. This research project focuses on identifying chromatin regulators required for enhancer hijacking in cancer genomes. The research addresses the fundamental mechanisms by which structural genomic variants aberrantly activate...
- Federal Grant Award Summary The National Cancer Institute awarded $125,619 to the Stowers Institute for Medical Research under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This Project Grant supports research into centromere biology and chromosome segregation mechanisms that contribute to genomic instability—a hallmark of cancer development. The primary deliverables include experimental research characterizing how natural...
The Sloan-Kettering Institute for Cancer Research received a $534,644 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded June 1, 2026, with completion targeted for January 31, 2030. This award supports fundamental research investigating the role of cohesin-STAG2 in R-loop homeostasis and its implications for cancer development. The research will examine how mutations in STAG2, the most frequently mutated cohesin subunit in human cancers, lead to accumulation of R-loops (RNA-DNA hybrid structures) and replication stress. Specifically, the project will dissect the molecular mechanisms underlying R-loop regulation, gene expression control, and the prevention of replication-transcription conflicts in normal and cancer cells. The funded research addresses a critical gap in understanding how STAG2 loss promotes tumorigenesis and identifies potential therapeutic vulnerabilities in STAG2-deficient cancer cells. Findings from this investigation are intended to inform the development of more effective and less toxic cancer therapies by elucidating how STAG2-deficient cells become dependent on specific R-loop mitigation pathways, including RNase H2 and the Fanconi anemia pathway. The award supports the Institute's broader cancer research portfolio and aligns with NIGMS's mission to support basic research that establishes the foundation for advances in disease diagnosis, treatment, and prevention.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $534.6k | 5/26/26 |